Publications by authors named "Pete Gorycki"
Fostemsavir is an approved gp120-directed attachment inhibitor and prodrug for the treatment of human immunodeficiency virus type 1 infection in combination with other antiretrovirals (ARVs) in heavily treatment-experienced adults with multi-drug resistance, intolerance, or safety concerns with their current ARV regimen. Initial in vitro studies indicated that temsavir, the active moiety of fostemsavir, and its metabolites, inhibited organic cation transporter (OCT)1, OCT2, and multidrug and toxin extrusion transporters (MATEs) at tested concentration of 100 uM, although risk assessment based on the current Food and Drug Administration in vitro drug-drug interaction (DDI) guidance using the mechanistic static model did not reveal any clinically relevant inhibition on OCTs and MATEs. However, a DDI risk was flagged with EMA static model predictions.
View Article and Find Full Text PDFArticle Synopsis
- Momelotinib, an approved treatment for myelofibrosis in adults with anemia, was studied for drug-drug interactions (DDIs) with different inhibitors and inducers affecting its metabolism, specifically looking at the impact of medications like ritonavir and rifampin.
- The study found that while coadministration with ritonavir and rifampin did increase momelotinib and its metabolite M21 exposure, these changes were not clinically significant.
- Momelotinib did not impact the metabolism of certain drugs, but it significantly altered the levels of rosuvastatin, indicating that monitoring and possible dose adjustments may be necessary for patients taking these medications together.